Latest Research, Industry, Medical and Scientific News
StimGuard, a privately-held, pre-commercial stage medical device company, today announced the initiation and the first patient enrollment in a clinical trial of the world’s first miniature implantable device for the treatment of urgency urinary incontinence resulting from refractory overactive bladder (OAB) syndrome. The StimGuard device utilizes wireless technology and is placed through an introducer device the size of a needle at the tibial nerve to activate the afferent micturition (neural urinary) pathways. The clinical trial of this novel approach will launch this winter. Read more.
Source: Business Wire, December 15, 2016
Cytori Therapeutics, Inc. (CYTX) today announced that over half of 45 patients in the ADRESU trial in Japan have been enrolled and treated. ADRESU is a late phase, investigator-initiated Japanese clinical trial to study the efficacy and safety of Cytori Cell TherapyTM in men with stress urinary incontinence after prostatic intervention for prostate cancer or benign prostatic hypertrophy. Read more.
Source: Yahoo! Finance, December 14, 2016
I have only one regret about not having been born a male, and it concerns plumbing, namely how easy it is for men to eliminate liquid waste, whether by avoiding long bathroom lines or being able to relieve themselves discreetly when no facility is available. My male envy grew after I contracted poison ivy on unmentionable parts when nature called during a hike in the woods. Urination has long been a vexing problem for women. Read more.
Source: New York Times, December 12, 2016
In a study of older women, the prevalence of stress- and urgency urinary incontinence (SUI and UUI) was at least two-fold higher among women in the highest category of body mass index (BMI) or fat mass compared with women in the lowest category. Also, women who lost at least 5% of their BMI or fat mass were less likely to experience new or persistent SUI over 3 years than women with less weight loss. Read more.
Source: EurekAlert, December 6, 2016
Innovus Pharmaceuticals, Inc. (“Innovus Pharma”) (OTCQB Venture Market: INNV), an emerging commercial-stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care products to improve men’s and women’s health and respiratory diseases, today announced the launch of UriVarx™ in the U.S. UriVarx™ is clinically proven to reduce urinary urgency, accidents and both day and night frequency in Overactive Bladder (“OAB”) and Urinary Incontinence (“UI”) patients. Read more.
Source: BusinessWire, December 1, 2016
It’s early morning and your teenage daughter runs out the door to school. Much will happen today that you may or may not hear about when you see her again tonight. It’s unlikely that you will hear anything about the school restrooms, yet during her day at school, your daughter is developing habits that can affect her bladder for her lifetime . Three hours into the school day your daughter needs to urinate but doesn’t ask to leave her class because she can’t afford to miss information that will be on this week’s exam. Also this teacher gives extra credit to students who don’t ask for bathroom breaks. A minute later her urge to urinate is gone. During her short passing period to lunch she walks by the restroom, but is too busy texting her friend and doesn’t stop. She eats her lunch and heads to her next class. Suddenly she feels her bladder again. She heads to the bathroom but turns around because the floor looks dirty. Sitting down in class she crosses her legs and does not feel her bladder so much, which is good because her teacher does not allow bathroom breaks right after lunch. Read more.
Source: Huffington Post, November 21, 2016